Acute and chronic toxicological studies of the Brazilian phytopharmaceutical product Ierobina

Ierobina® is a Brazilian phytopharmaceutical product employed for the treatment of dyspepsia (280 mg/kg/day). Despite its widespread use in the country for over 75 years, only recently its therapeutic efficacy has been attested in animals; however, no toxicological investigations have been carried out for the product to date. In this paper we evaluated the acute toxicity of Ierobina® administrated by gavage in mice (single doses of 2100 mg/kg, 6300 mg/kg and 12600 mg/kg), along with its chronic effects in rats, after product administration per os daily, at the doses of 2800 mg/kg and 5600 mg/kg, for 180 days. The product had low acute toxicity; all observed alterations were reversible and no animal died during the experiments. In chronic toxicological studies, Ierobina® administration for 180 days did not cause any changes in hematological and biochemical parameters, with the exception of decreasing the levels of alanine transaminase, aspartate transaminase and creatinine. However, histological evaluation of kidney, liver and other selected organs showed normal architecture, suggesting no morphological disturbances. Hence, considering the obtained results and the fact that Ierobina® has been commercialized for decades in Brazil, without any notified case of toxicity, it seems that the product is safe for human use